Coherus Oncology, formerly known as Coherus BioSciences, is a U.S.-based commercial-stage biopharmaceutical company focused on immuno-oncology. Founded in 2010 and led by Chief Executive Officer Denny Lanfear, the company has moved away from its legacy biosimilar business—divesting products such as UDENYCA, Cimerli, and Yusimry—to concentrate on cancer immunotherapies. Its lead commercial asset is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved for nasopharyngeal carcinoma. The clinical pipeline is anchored by tagmokitug, an investigational anti-CCR8 antibody, and casdozokitug, an anti-IL-27 antibody. Investors follow CHRS primarily for LOQTORZI's commercial ramp and the pipeline's clinical readouts, balanced against a cash-constrained balance sheet and execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, CHRS has declined from approximately $1.02 to near $0.39, a drop of roughly 62%. Most of the move was concentrated in early-to-mid November following the company's third-quarter report. The longer-term trend is even steeper: shares traded near $1.32 in mid-August and now sit near $0.39, a decline of about 71% over the trailing quarter. The stock has been in a sustained downtrend through 2026, well below its 52-week high near $2.62, as persistent cash burn and financing overhang have outweighed clinical progress.
The sharp decline was triggered by the company's third-quarter 2026 results, reported in early November. Coherus posted a non-GAAP loss of $0.20 per share on revenue of $14.27 million, short of the roughly $15.9 million consensus, with LOQTORZI net sales of $14.0 million. Management cut full-year LOQTORZI guidance to $54–$57 million from $57–$62 million and disclosed going-concern language in its quarterly filing, noting a cash runway of less than 12 months. Cash and investments fell to $83.6 million from $105.3 million at the end of the second quarter and $172.1 million at year-end. To preserve capital, the company announced a roughly 30% workforce reduction, from about 140 to 100 employees, expected to save $6–$7 million per quarter, and refinanced its term loan, adding about $11.5 million in net cash. A $50 million at-the-market equity program established in August added to dilution concerns. Positive tagmokitug plus toripalimab data in second-line esophageal cancer—a 33.3% confirmed response rate—provided a clinical bright spot, but the balance-sheet narrative dominated investor sentiment.
The quarterly decline reflects a broader multi-month story of tightening liquidity. With LOQTORZI as its only marketed product and quarterly sales still well below breakeven, Coherus has relied on cost cuts and financing to extend its runway. Over the quarter, the company trimmed expenses, narrowed its pipeline toward esophageal cancer, and sought capital through equity and debt transactions. Although clinical signals from tagmokitug and casdozokitug kept the long-term thesis alive, repeated financing steps, missed revenue expectations, and the going-concern disclosure progressively reset the stock's valuation lower.
Investors should monitor several factors that could shape CHRS going forward. LOQTORZI's commercial execution is central, with management targeting roughly $15 million in fourth-quarter revenue and a path toward a $25–$30 million quarterly breakeven. Regulatory developments are also key: Coherus plans to meet with the FDA on tagmokitug dosing and a second-line esophageal cancer study design, with potential for an expedited or accelerated approval pathway. Balance-sheet items remain critical, including potential ex-U.S. partnering for tagmokitug, UDENYCA divestiture milestone payments, and any additional financing. With the stock trading below $1, listing-compliance considerations and ongoing cash-burn trends will also remain in focus. From what I see, I’m watching this closely as these elements could influence the next moves.
In my analysis of stocks like CHRS, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might respond to similar situations. These tools help review performance across various market conditions and can offer additional perspectives on trading approaches without replacing individual judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CHRS saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.596). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology